Clinical Trial

Treatment of Metastatic Melanoma

Study Description

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Spartalizumab

400 mg every 4 weeks intravenously (i.v)

Drug - LAG525

Taken intravenously (i.v)

Drug - Capmatinib

Taken orally

Drug - Canakinumab

Taken subcutaneusly (s.c)

Drug - Ribociclib

Taken orally

Additional Information

Official Study Title

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

Clinical Trial ID

NCT03484923

ParticipAid ID

NbW5oe